John Chung

3.5k total citations · 1 hit paper
14 papers, 1.6k citations indexed

About

John Chung is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Neurology. According to data from OpenAlex, John Chung has authored 14 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Endocrinology, Diabetes and Metabolism, 3 papers in Molecular Biology and 3 papers in Neurology. Recurrent topics in John Chung's work include Thyroid Cancer Diagnosis and Treatment (7 papers), Cancer therapeutics and mechanisms (3 papers) and Neuroblastoma Research and Treatments (3 papers). John Chung is often cited by papers focused on Thyroid Cancer Diagnosis and Treatment (7 papers), Cancer therapeutics and mechanisms (3 papers) and Neuroblastoma Research and Treatments (3 papers). John Chung collaborates with scholars based in United States, Germany and France. John Chung's co-authors include Young Kee Shong, Marcia S. Brose, Johannes W. A. Smit, Steven I. Sherman, Christopher M. Nutting, Martin Schlumberger, Christian Kappeler, Furio Pacini, Christelle de la Fouchardière and Lars Bastholt and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and The Journal of Urology.

In The Last Decade

John Chung

14 papers receiving 1.5k citations

Hit Papers

Sorafenib in radioactive iodine-refractory, locally advan... 2014 2026 2018 2022 2014 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
    2014 1.2k citations Marcia S. Brose, Christopher M. Nutting et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John Chung United States 11 1.1k 477 329 223 206 14 1.6k
Yifah Yaron United States 11 632 0.6× 615 1.3× 336 1.0× 382 1.7× 156 0.8× 17 1.4k
Jessica Read United Kingdom 9 762 0.7× 733 1.5× 428 1.3× 514 2.3× 181 0.9× 11 1.6k
Yu-Nien Sun United States 10 527 0.5× 566 1.2× 528 1.6× 332 1.5× 145 0.7× 12 1.4k
Qinghai Ji China 24 994 0.9× 262 0.5× 339 1.0× 162 0.7× 151 0.7× 66 1.5k
Alessandra Spitale Switzerland 11 791 0.7× 608 1.3× 187 0.6× 236 1.1× 233 1.1× 22 1.5k
В. С. Медведев Russia 4 521 0.5× 397 0.8× 207 0.6× 242 1.1× 118 0.6× 11 950
David Viola Italy 25 2.0k 1.9× 580 1.2× 589 1.8× 238 1.1× 378 1.8× 57 2.5k
Keiichi Nakano Japan 19 884 0.8× 248 0.5× 365 1.1× 60 0.3× 152 0.7× 45 1.4k
A Boneu France 15 507 0.5× 365 0.8× 201 0.6× 138 0.6× 114 0.6× 30 1.2k
Ramona Dadu United States 30 1.8k 1.7× 1.5k 3.1× 477 1.4× 396 1.8× 460 2.2× 94 2.9k

Countries citing papers authored by John Chung

Since Specialization
Citations

This map shows the geographic impact of John Chung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Chung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Chung more than expected).

Fields of papers citing papers by John Chung

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Chung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Chung. The network helps show where John Chung may publish in the future.

Co-authorship network of co-authors of John Chung

This figure shows the co-authorship network connecting the top 25 collaborators of John Chung. A scholar is included among the top collaborators of John Chung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Chung. John Chung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Morcos, Peter N., Rolf Burghaus, Jonathan Moss, et al.. (2023). Model‐informed approach to support pediatric dosing for the pan‐PI3K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors. Clinical and Translational Science. 16(7). 1197–1209. 3 indexed citations
2.
Casanova, Michela, Francisco Bautista, Quentin Campbell Hewson, et al.. (2020). Phase I study of regorafenib in combination with vincristine and irinotecan in pediatric patients with recurrent or refractory solid tumors.. Journal of Clinical Oncology. 38(15_suppl). 10507–10507. 6 indexed citations
3.
Reck, Martin, Leora Horn, Silvia Novello, et al.. (2019). Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(4). 701–711. 50 indexed citations
4.
Bulat, Iurie, Kathleen N. Moore, John Chung, et al.. (2018). Phase Ib study of anti-mesothelin antibody drug conjugate anetumab ravtansine in combination with pegylated liposomal doxorubicin in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.. Journal of Clinical Oncology. 36(15_suppl). 5571–5571. 13 indexed citations
5.
Worden, Francis P., Martin Faßnacht, Yuankai Shi, et al.. (2015). Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer. Endocrine Related Cancer. 22(6). 877–887. 47 indexed citations
6.
Brose, Marcia S., Christopher M. Nutting, Barbara Jarząb, et al.. (2014). Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. The Lancet. 384(9940). 319–328. 1153 indexed citations breakdown →
7.
Worden, Francis P., Martin Faßnacht, Yuankai Shi, et al.. (2014). Safety and tolerability of sorafenib for treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC): Detailed analyses from the phase III DECISION trial.. Journal of Clinical Oncology. 32(15_suppl). 6062–6062. 4 indexed citations
8.
Brose, Marcia S., Barbara Jarząb, Rossella Elisei, et al.. (2014). Updated overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib on the phase 3 DECISION trial.. Journal of Clinical Oncology. 32(15_suppl). 6060–6060. 27 indexed citations
9.
Brose, Marcia S., Christopher M. Nutting, Barbara Jarząb, et al.. (2013). Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial.. Journal of Clinical Oncology. 31(15_suppl). 4–4. 61 indexed citations
10.
Brose, Marcia S., Christopher M. Nutting, Barbara Jarząb, et al.. (2013). Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial.. Journal of Clinical Oncology. 31(18_suppl). 4–4. 41 indexed citations
11.
12.
Chung, John & R. van Mastrigt. (2009). Age and Volume Dependent Normal Frequency Volume Charts for Healthy Males. The Journal of Urology. 182(1). 210–214. 19 indexed citations
13.
Cheung, Nai‐Kong V., Shakeel Modak, Yukang Lin, et al.. (2004). Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2.. PubMed. 45(5). 867–77. 46 indexed citations
14.
Morimatsu, Hiroshi, Shigehiko Uchino, John Chung, et al.. (2003). Norepinephrine for hypotensive vasodilatation after cardiac surgery: impact on renal function. Intensive Care Medicine. 29(7). 1106–1112. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yifah Yaron Breakdown of academic impact, for papers by Jessica Read Breakdown of academic impact, for papers by Yu-Nien Sun Breakdown of academic impact, for papers by Qinghai Ji Breakdown of academic impact, for papers by Alessandra Spitale Breakdown of academic impact, for papers by В. С. Медведев Breakdown of academic impact, for papers by David Viola Breakdown of academic impact, for papers by Keiichi Nakano Breakdown of academic impact, for papers by A Boneu Breakdown of academic impact, for papers by Ramona Dadu
Rankless by CCL
2026